- Madrigal Pharmaceuticals just came out with positive new data for its treatment of a “silent” disease millions are living with.
- The condition, NASH, short for nonalcoholic steatohepatitis, is a type of liver disease in which liver fat builds up in people. There are no approved treatments for NASH, though there are some in late-stage development with data expected in 2019.
- Madrigal showed in a phase 2 study with 73 patients that its treatment was better than placebo at reducing fat in the liver, and the treatment managed to resolve NASH in 27% of the patients who received treatment, compared to just 6% of those in the placebo group.
- Madrigal’s stock was up 60% before markets opened on Thursday on the results.
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.